Oxford Biomedica Solutions signs agreement with new partner for AAV platform

Gene and cell therapy group Oxford Biomedica has announced that its subsidiary Oxford Biomedica Solutions has signed an agreement with a new undisclosed US-based private biotechnology company.

Oxford Biomedica Solution is a high-performing full-scope scope manufacturing and innovation business in the field of adeno associated virus (AAV) gene therapy.

The agreement grants the partner access to Oxford Biomedica Solutions’ process and manufacturing platform, and “The Full Solution” service offering, with end-to-end capabilities for their pre-clinical gene therapy programmes.

Under the terms of the agreement, Oxford Biomedica Solutions will receive payments relating to the full scope of process development, from construct design through to toxicology manufacturing for the partner’s programmes.

Dr. Roch Doliveux, Chair and Interim CEO of Oxford Biomedica, said: “We are delighted to announce this new AAV partnership, and look forward to offering Oxford Biomedica Solutions’ full-scope platform to our new partner and supporting them with their construct design and product development needs.

"This agreement marks a very important step towards achieving our strategic objective of becoming a global viral vector leader across all key vector types, delivering life changing therapies to patients.”